---
title: Patentability of Antibodies Under the EPC
description: Explore the EPO requirements for patentability of monoclonal antibodies, featuring leading decisions and updated guidelines, in our webinar on June 11, 2025.
image: https://www.jacobacci.com/hubfs/webinar-patentability_of_antibodies-cover-900x600_20250305%20(2).jpg
---

- [Customer Area](https://www.jacobacci.com/en/customer-area/)
- [Supplier Area](https://www.jacobacci.com/en/supplier-area/)
- [Contacts](https://www.jacobacci.com/en/contacts/)
- [**](http://www.linkedin.com/company/jacobacci-%26-partners-s.p.a.)
- [**](https://www.facebook.com/JacobacciPartners)
- [**](https://www.instagram.com/jacobacciip/)
- [**](http://www.youtube.com/JacobacciPartners)
- [IT](https://www.jacobacci.com/?hsLang=it)
- ** THE GROUP 
    - [FRANCE](https://jch.jacobacci.com/fr/?hsLang=fr)

# Patentability of Antibodies Under the EPC

- [Home](https://www.jacobacci.com/en/)

**9 June 2025 ** [Patents](https://www.jacobacci.com/en/webinar/tag/patents) ** Jacobacci & Partners

![Patentability of antibodies_no-label](https://www.jacobacci.com/hs-fs/hubfs/Patentability%20of%20antibodies_no-label.jpg?width=825&height=464&name=Patentability%20of%20antibodies_no-label.jpg)In view of the ever-growing developments in antibody technology in the pharmaceutical field, patent protection of monoclonal antibodies is of paramount importance for innovators and research scientists.

Whereas an antibody is a molecular structure and therefore subject to the same patentability requirements of other (chemical) products, the unique biological and physiological features of these large proteinaceous molecules lead to peculiarities for their patent protection.

The webinar on 11 June, in partnership with IIT Istituto Italiano di Tecnologia, aimed to review the EPO requirements for patentability of antibodies, including:

- ![🎯](https://www.jacobacci.com/hs-fs/hubfs/undefined-Jun-06-2025-12-56-31-9331-PM.png?width=1&height=1&name=undefined-Jun-06-2025-12-56-31-9331-PM.png ":dart:") the suitable definition of an antibody in a patent claim, so as to meet the clarity requirement;
- ![🎯](https://www.jacobacci.com/hs-fs/hubfs/undefined-Jun-06-2025-12-56-31-9331-PM.png?width=1&height=1&name=undefined-Jun-06-2025-12-56-31-9331-PM.png ":dart:") the evidence required to meet the novelty, inventive step and sufficiency of disclosure requirements.

Said requirements will be discussed in view some leading decisions of the EPO Board of Appeal and in view of the Guidelines for Examination in the EPO, which were revised in 2025 to include a specific section on antibodies that officially implements the previously developed Case Law.

**![🎤](https://www.jacobacci.com/hs-fs/hubfs/undefined-Jun-06-2025-12-57-19-7967-PM.png?width=1&height=1&name=undefined-Jun-06-2025-12-57-19-7967-PM.png ":microphone:")Speakers: [Elena Comoglio](https://www.jacobacci.com/en/professionals/elena-comoglio), ****[Paolo Rambelli](https://www.jacobacci.com/en/professionals/paolo-rambelli)**

 

**

#### Categories

- [AI](https://www.jacobacci.com/en/webinar/tag/ai)
- [Designs](https://www.jacobacci.com/en/webinar/tag/designs)
- [Patents](https://www.jacobacci.com/en/webinar/tag/patents)
- [Start-up](https://www.jacobacci.com/en/webinar/tag/start-up)
- [Trademarks](https://www.jacobacci.com/en/webinar/tag/trademarks)

#### Popular articles

[![3D Trademarks: the Vespa scooter case](https://www.jacobacci.com/hubfs/Webinar/3D%20trademarks%20-%20The%20Vespa%20scooter%20case/cover-webinar-vespa-ENG.jpg)](https://www.jacobacci.com/en/webinar/3d-trademarks-the-vespa-scooter-case)

[3D Trademarks: the Vespa scooter case](https://www.jacobacci.com/en/webinar/3d-trademarks-the-vespa-scooter-case) 20 April 2021

[![Artificial Intelligence and Intellectual Property: rights, protections and legal challenges](https://www.jacobacci.com/hubfs/cover_AI%20e%20IP_250527_EN_-1.jpg)](https://www.jacobacci.com/en/webinar/artificial-intelligence-and-intellectual-property)

[Artificial Intelligence and Intellectual Property: rights, protections and legal challenges](https://www.jacobacci.com/en/webinar/artificial-intelligence-and-intellectual-property) 27 May 2025

[![From lab to life: the pharma product journey](https://www.jacobacci.com/hubfs/Webinar_Pharma-blogpost_900x512.jpg)](https://www.jacobacci.com/en/webinar/from-lab-to-life-the-pharma-product-journey)

[From lab to life: the pharma product journey](https://www.jacobacci.com/en/webinar/from-lab-to-life-the-pharma-product-journey) 26 September 2025

[![The Role of Technically Qualified Judges (TQJs) in the UPC](https://www.jacobacci.com/hubfs/UPC%20mattonella%20anteprima.jpg)](https://www.jacobacci.com/en/webinar/the-role-of-technically-qualified-judges-in-the-upc)

[The Role of Technically Qualified Judges (TQJs) in the UPC](https://www.jacobacci.com/en/webinar/the-role-of-technically-qualified-judges-in-the-upc) 19 March 2025

[![Patentability of Antibodies Under the EPC](https://www.jacobacci.com/hubfs/webinar-patentability_of_antibodies-cover-900x600_20250305%20(2).jpg)](https://www.jacobacci.com/en/webinar/patentability-of-antibodies-under-the-epc)

[Patentability of Antibodies Under the EPC](https://www.jacobacci.com/en/webinar/patentability-of-antibodies-under-the-epc) 9 June 2025

[**](https://www.jacobacci.com/en/webinar/patentability-of-antibodies-under-the-epc#)

 Cookie Settings